22nd Century Group is also helping New Zealand become less tobacco-dependent New York-based 22nd Century Group, Inc. (XXII) is known for developing plant-based solutions for
A recent regulatory approval should thrust TRACON’s antibody-based tumor-fighting therapy into a broad, lucrative geographic market The battle against cancer is ongoing, and not limited
As the data proves, ReShape’s direct-to-consumer marketing campaign has been a huge success A vast patient population, and an already FDA-approved product – there are
The runway is cleared now that Phunware’s next-gen platform is listed on Amazon’s AWS Marketplace Based in Austin, Texas, Phunware, Inc. (PHUN) doesn’t call itself
From elder care and telemedicine to neutraceuticals and more, Novo offers a broad range of solutions Imagine being able to diversify your holdings in the
NeuBase is accelerating the genetic revolution with a new class of broad-based but highly targeted medicines Based in Pittsburgh, Pennsylvania, NeuBase Therapeutics, Inc. (NBSE) is
Bet on a reduced-risk, global innovator in drug delivery platforms with Lexaria There are plenty of biotechnology businesses that focus entirely on novel drugs. But
There’s no denying the results as Clene revolutionizes the treatment of neurodegenerative disease Seven-figure funding has obvious financial benefits for any business. When it comes
Aravive’s cancer-fighting therapy is targeted, transformative, and fast-tracked for success A number of deadly and difficult-to-treat diseases, including cancer and fibrosis, share a common underlying
Multiple patent families and clinical programs empower Inhibikase to combat neuro-degenerative diseases – and serve a vast market It’s tragic: Parkinson’s disease is responsible for
Stockpence is currently seeking to expand our team of contributors. We’re looking for financial gurus & article writers to write about trending market news and investment ideas about the stock market.
If you’re interested please contact us!
Investing involves substantial risk. Neither the authors, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the articles herein. No reader should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, on any featured company here.
Some of the companies featured here may pay a fee to an affiliate of the publication to broaden awareness of said company.
The principals of the publication may buy or sell shares of the featured companies from time-to-time.
Join our free mailing list below to receive real-time news alerts and our next featured stock!
Investing involves substantial risk. Neither the Authors, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the articles herein. No reader should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, on any featured company here.
Some of the companies featured here may pay a fee to an affiliate of the publication to broaden awareness of said company.
The principals of the publication may buy or sell shares of the featured companies from time-to-time.
Join our free mailing list below to receive real-time news alerts and our next featured stock!
